Logo

ESG Data

アンカーリンク用

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Category Item Scope Unit FY2016 FY2017 FY2018
Corporate Governance Structure Board structure Directors (Total) Non-consolidated Persons 7 7  8
Independent outside directors Non-consolidated Persons 2 2  3
Female directors Non-consolidated Persons 0 0 0
Board of Auditors structure Auditors (Total) Non-consolidated Persons 5 4  4
Independent outside auditors Non-consolidated Persons 3 2  2
Female auditors Non-consolidated Persons 1 1 1
Director Remuneration Total Non-consolidated Million yen 345 336 360
President, Representative Director, and Chief Executive Officer Non-consolidated JPY million - - 114
Auditor Remuneration Total Non-consolidated Million yen 71 76 77
Number of Board of Directors meetings   Times 15 13  13
Number of Board of Auditors meetings   Times 13 13  14
Board attendance rate(directors)   %  - 100.0 100.0
Board attendance rate(auditors)   %  -  - 100.0
Compliance Compliance training attendance rate Non-consolidated % - - 100
Number of reports to ONO Hotline and internal contacts Non-consolidated Cases - - 44
Number of disciplinary actions Non-consolidated Cases - - 5
Number of bribery cases Non-consolidated Cases 0 0 0
Number of facilitation payments Non-consolidated Cases 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

Innovative Pharmaceutical Products
Category Item Scope Unit FY2016 FY2017 FY2018
Research Development R&D expenses Non-consolidated Million yen 57,506 68,821  70,008
Ratio of R&D expenses to net sales Non-consolidated 23.5 26.3  24.3
Human Resources and Human Rights
Category Item Scope Unit FY2016 FY2017 FY2018
Provision of Growth Opportunities Company-wide joint training implementation status Workshop for understanding/spreading our mission statement Non-consolidated Participants × hours - 943 317
Non-consolidated Participants - 145 56
Orientation for newly hired employees
Follow-up training for newly hired employees
Non-consolidated Participants × hours - 9,408 7,682
Non-consolidated Participants - 98 86
Third-year employee training
Fifth-year employee training
Non-consolidated Participants × hours - 3,040 1,667
Non-consolidated Participants - 190 164
Training for individual contributors promoted to the highest level
Training for new core employees
Training for new managers
Manager training
Non-consolidated Participants × hours - 11,968 11,653
Non-consolidated Participants - 748 1,027
Coaching training Non-consolidated Participants × hours - 1,950 992
Non-consolidated Participants - 78 37
Training for selected employees Non-consolidated Participants × hours - 5,063 5,471
Non-consolidated Participants - 61 94
English training Non-consolidated Participants × hours - 11,988 19,215
Non-consolidated Participants - 111 260
Diversity management training Non-consolidated Participants × hours - 108 1,529
Non-consolidated Participants - 27 734
Career planning training Non-consolidated Participants × hours - 1,362 426
Non-consolidated Participants - 190 142
Voluntary training (Correspondence courses/online English conversation classes) Non-consolidated Participants × hours - 2,604 2,513
Non-consolidated Participants - 217 231
Annual training hours per employee Non-consolidated Hours - - 35.5
Promoting active participation of persons with disabilities/mid-career employment Employment of persons with disabilities Non-consolidated % 2.30 2.24 2.28
Mid-career employment Non-consolidated Persons 322 380 440
Employee composition Male ratio of new graduates Non-consolidated % 66 51 66
Female ratio of new graduates Non-consolidated % 34 49 34
Male Non-consolidated Persons 2,358 2,629 2,682
Female Non-consolidated Persons 524 570 602
Total Non-consolidated Persons 3,062 3,199 3,284
Contract workers ratio Non-consolidated % - 0.3 0.1
Temporary staff ratio Non-consolidated % - 8.8 8.9
Average age (male) Non-consolidated Years old 41.1 42.1 42.6
Average age (female) Non-consolidated Years old 37.1 37.9 38.0
Average age (total) Non-consolidated Years old 40.4 41.4 41.8
Average consecutive years of employment(male) Non-consolidated Years 15.9 16.0 16.3
Average consecutive years of employment(female) Non-consolidated Years 12.3 11.8 12.0
Average consecutive years of employment(total) Non-consolidated Years 15.3 15.3 15.5
Employee information Average annual salary Non-consolidated JPY 10,000 897 906 917
Labor union participation rate Non-consolidated % 68.6 66.8 65.1
Employee satisfaction rate (male) Non-consolidated % - - 68
Employee satisfaction rate (female) Non-consolidated % - - 57
Employee satisfaction rate (all) Non-consolidated % 62 - 66
Female manager rate Non-consolidated % 3.4 3.9 4.0
Turnover and retention rate Retention rate after 3 years(male) Non-consolidated 93.1 98.4 96.1
Retention rate after 3 years(female) Non-consolidated 85.4 96.9 100.0
Retention rate after 3 years(total) Non-consolidated 89.9 97.8 97.8
Full-time employee turnover rate(voluntary resignation) Non-consolidated 1.0 1.3 1.5
Full-time employee turnover rate(Mandatory retirement, etc.) Non-consolidated 0.9 0.7 0.6
Full-time employee turnover rate(total) Non-consolidated 1.9 2.0 2.1
Safety and Health
Category Item Scope Unit FY2016 FY2017 FY2018
Enhancing cultivation of employee-friendly workplaces Working hours Non-consolidated % compared to previous year N/A ▽0.5% ▽5.7%(compared to FY2014)
Percentage of paid vacation taken Non-consolidated % compared to previous year N/A △6.4% △17.2%(compared to FY2014)
Number of lost-time injuries Lost-time injury Pre-FY2016: Japanesefactories and research sites
Post-FY2017:All Japanese operation sites
Incidents 1* 1 1
Severity Rate Pre-FY2016: Japanesefactories and research sites
Post-FY2017:All Japanese operation sites
- 0.16 0.16 0.15
Supporting disease prevention, early detection and early treatment Medical checkups received Non-consolidated - 99.1 99.4
Cancer screening rate Stomach cancer screening Non-consolidated - 97.2 97.3
Lung cancer screening Non-consolidated - 99.3 99.7
Colorectal cancer screening Non-consolidated - 93.9 93.6
Breast cancer screening Non-consolidated - 90.0 88.3
Cervical cancer Non-consolidated - 43.4 42.3
Mental health Stress checks received Non-consolidated - 95.1 97.8
Health promotion Number of participants in walking campaign Employees Non-consolidated Persons 887 1,088 1,169
Family Non-consolidated Persons 256 472 771
Temporary staff, etc. Non-consolidated Persons 68 99 90
Walking campaign total employee participation rate Non-consolidated - 34 35

*A part of previous data has been revised due to the detailed check of the data.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

Energy Saving and Global Warming Prevention
Category Item Scope Unit FY2016 FY2017 FY2018
CO2 emissions Energy-derived CO2 emissions Production and research sites 10,000 t-CO2 2.40 2.40  2.52
Headquarters and other Sites in Japan(including tenant locations) 10,000 t-CO2 0.22 0.22  0.22
Total 10,000 t-CO2 2.62 2.62  2.74
Energy-derived CO2 emissions scope breakdown Scope 1 All operation sites 10,000 t-CO2 -  0.85  0.90
Scope 2 Location-basis All operation sites 10,000 t-CO2 -  1.77  1.85
Market-basis All operation sites 万t-CO2 -  -   1.95
CO2 emissions in the value chain Scope 3 Purchased goods and services Sites in Japan 10,000 t-CO2 9.71 0.85*1 -*2
Capital goods Sites in Japan 10,000 t-CO2 2.70 5.26 6.04
Fuel- and energy-related activities not included in scope 1 or scope 2 Sites in Japan 10,000 t-CO2 0.15 0.15  0.15
Upstream transportation and distribution Sites in Japan 10,000 t-CO2 0.01 0.01  0.01
Waste generated in operations Sites in Japan 10,000 t-CO2 0.03 0.03 0.03
Business travel Sites in Japan 10,000 t-CO2 0.22 0.25  0.23
Employee commuting Sites in Japan 10,000 t-CO2 0.03 0.04  0.04
Upstream leased assets Sites in Japan 10,000 t-CO2 0.35 0.35  0.33
Downstream transportation and distribution Sites in Japan 10,000 t-CO2 0.62 0.53 -*2
Processing of sold products Sites in Japan 10,000 t-CO2 Not calculated Not calculated Not calculated
Use of sold products Sites in Japan 10,000 t-CO2 Not calculated Not calculated Not calculated
End-of-life treatment of sold products Sites in Japan 10,000 t-CO2 0.02 0.01 0.01 
Downstream leased assets Sites in Japan 10,000 t-CO2 0.03 0.03 0.03 
Franchises Sites in Japan 10,000 t-CO2 Not calculated Not calculated Not calculated
Investments Sites in Japan 10,000 t-CO2 Not calculated Not calculated Not calculated
Total Sites in Japan 10,000 t-CO2 13.87 7.51*1 -*2
Energy consumption Energy consumption Production and research sites 10,000 GJ 52.72 52.65 55.42 
Headquarters and other Japan offices/sites(including tenant locations) 10,000 GJ 5.04 5.10 5.13 
Total 10,000 GJ 57.76 57.74 60.55
Renewable energy amount Solar power generation (by private power generation) Sites in Japan MWh 53.96 55.29 64.97
Biomass power generation (by purchase) Sites in Japan MWh -  -  2,900
  • ※1 Calculation method of category 1 in Scope 3, “Purchased goods and services”, was changed from FY2017.
    FY2016 and previous fiscal years: Purchase cost of raw materials, materials, etc., multiplied by emission factor stated in “Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (ver. 2 .4),” published by the Ministry of the Environment, Government of Japan.
    FY2017: CO2 emissions(Scope 1,2) volume of our raw materials and materials suppliers (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of CO2 emissions to the transaction amount at major suppliers.
  • ※2 Because our major business partners had not published their CSR reports at the time of calculation.
Efforts Made for Reducing Water Use
Category Item Scope Unit FY2016 FY2017 FY2018
Water intake Water intake   Fujiyama Plant/Joto Pharmaceutical Product Development Center/MinaseResearch Institute/Fukui Research Institute/Tsukuba Research Institute 10,000 m3 29.84 30.92 33.29
Water intake per site Fujiyama Plant 10,000 m3 19.57 20.56 24.02
Joto Pharmaceutical Product Development Center 10,000 m3 0.72 0.55 0.60
Minase Research Institute 10,000 m3 4.52 5.13 4.12
Fukui Research Institute 10,000 m3 3.94 3.87 3.13
Tsukuba Research Institute 10,000 m3 1.09 0.81 0.60
Yamaguchi Plant 10,000 m3 - - 0.82
Wastewater Wastewater   Fujiyama Plant/Joto Pharmaceutical Product Development Center/Minase Research Institute/Fukui Research Institute/Tsukuba Research Institute 10,000 m3 19.97 21.87 24.48
Wastewater site Fujiyama Plant 10,000 m3 12.89 14.86 17.84
Joto Pharmaceutical Product Development Center 10,000 m3 0.72 0.55 0.60
Minase Research Institute 10,000 m3 4.52 5.13 4.12
Fukui Research Institute 10,000 m3 0.75 0.52 0.50
Tsukuba Research Institute 10,000 m3 1.09 0.81 0.60
Yamaguchi Plant 10,000 m3 -  -  0.82
Percentage of reused water   Production and research sites % -  5.90 4.60
Waste Management, and Recycling Containers and Product Packaging
Category Item Scope Unit FY2016 FY2017 FY2018
Waste Industrial waste Waste generated Production and research sites t 534.6 719.1 446.4
Direct landfill disposal Production and research sites t 0.7 7.4 0.4
 Amount of waste landfilled (Non-industrial waste is included) Production and research sites t 10.66 18.04 9.35
Container and packaging usage Plastic Production and research sites t -  164.7 171.7
Paper Production and research sites t -  192.0 202.7
Glass (colorless) Production and research sites t -  0 0
Glass (brown) Production and research sites t -  0.3 0.3
Obligatory recycling amount Plastic Production and research sites t -  34.7 35.5
Paper Production and research sites t -  1.6 1.6
Glass (colorless) Production and research sites t -  0 0
Glass (brown) Production and research sites t -  0 0
Commissioning fee paid for recycling Production and research sites 1,000 yen -  1,723 1,650
PRTR substance Production and research sites t 10.94 11.79 9.76
Prevention of Air Pollution and Water Pollution
Category Item Scope Unit FY2016 FY2017 FY2018
Emissions into the air SOx Production and research sites t 0.00 0.00 0.00
NOx Production and research sites t 13.80 7.812 8.38
Particulate matter Production and research sites t 0.42 0.34 0.28
PRTR substance Production and research sites t 0.20 0.36 0.25
Emissions into water Wastewater Production and research sites 10,000 m3 19.97 21.87 24.48
BOD Production and research sites t 2.38 2.22 1.27
PRTR substance Production and research sites t 0.00 0.00 0.00
Management of Chemicals
Category Item Scope Unit FY2016 FY2017 FY2018
PRTR substances Amount handled by the notified facilities Acetonitrile Production and research sites t 8.29 8.98 7.19
Normal-hexane Production and research sites t 2.95 2.97 2.82
Total Production and research sites t 11.24 11.95 10.01
Notified release(into the air) Acetonitrile Production and research sites t 0.20 0.36 0.25
Normal-hexane Production and research sites t 0.00 0.00 0.00
Total Production and research sites t 0.20 0.36 0.25
Notified release(into public waters) Acetonitrile Production and research sites t 0.00 0.00 0.00
Normal-hexane Production and research sites t 0.00 0.00 0.00
Total Production and research sites t 0.00 0.00 0.00
Notified transfer(contained in waste) Acetonitrile Production and research sites t 8.09 8.82 6.94
Normal-hexane Production and research sites t 2.85 2.97 2.82
Total Production and research sites t 10.94 11.79 9.76
Notified transfer(Into public sewage) acetonitrile Production and research sites t 0.00 0.00 0.00
Normal-hexane Production and research sites t 0.00 0.00 0.00
Total Production and research sites t 0.00 0.00 0.00
Notified release and transfer (total) acetonitrile Production and research sites t 8.29 8.98 7.19
Normal-hexane Production and research sites t 2.95 2.97 2.82
Total Production and research sites t 11.24 11.95 10.01
PCB Joto Pharmaceutical Product Development Center Stored(Fluorescent lamp) Production and research sites 552 552 552
Disposed Production and research sites Stand 6 6 6
Minase Research Institute Disposed Production and research sites Stand 2 2 2
CFC calculated leakage of fluorocarbons Production and research sites t-CO2 -  197.9 494.4
Green Purchasing
Category Item Scope Unit FY2016 FY2017 FY2018
Green Purchasing office supplies purchased Non-consolidated 83 80 76
Environmental Management
Category Item Scope Unit FY2016 FY2017 FY2018
Management Acquisition status of ISO14001 Production site site 100% 100% 100%

*Production sites in operation are 100% ISO14001 certified.
Environmental Violations
Category Item Scope Unit FY2016 FY2017 FY2018
Environmental Violations Violation cases (with fines of USD 10,000 or more) Non-consolidated Cases 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Social Contribution Activities
Category Item Scope Unit FY2016 FY2017 FY2018
Initiatives for medical advancement Osamu Hayaishi Memorial Award   Persons -  1 1
Recipients of theresearch grant   Persons 12 12 12
Recipients of theresearch scholarship grant(40 years old and below)   Persons 16 16 16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad   Persons 8 8 8
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system
ESG Data
ESG Data

アンカーリンク用

Governance Data Social Data Environmental Data Social Contribu...

ESG Data
ESG Data

Governance Data

Corporate Governance ...

ESG Data
ESG Data

Social Data

Innovative Pharmaceutical Products ...

ESG Data
ESG Data

Environmental Data

Energy Saving and Global Warming Prevention ...

ESG Data
ESG Data

Social Contribution Activities Data

Social Contribution Activities ...